2023
Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection (Small Methods 10/2023)
Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection (Small Methods 10/2023). Small Methods 2023, 7 DOI: 10.1002/smtd.202370057.Peer-Reviewed Original Research
2016
Cellular Immunophenotyping: Industrial Technologies and Emerging Tools
Brower K, Fan R. Cellular Immunophenotyping: Industrial Technologies and Emerging Tools. 2016, 57-74. DOI: 10.1002/9783527801312.ch3.Peer-Reviewed Original ResearchCellular immune phenotypeHeterogeneous immune cellsImmune cell phenotypingPatient's immune statusDifferent patient cohortsImmune effector functionsDrug efficacy testingCellular immunityImmune statusPatient cohortImmune cellsImmune phenotypePatient responseEffector functionsDisease prognosisClinical settingCell phenotypingEfficacy testingGold standardCell populationsEffector moleculesImmunitySurface marker detectionPrognosisCohort